Publication & Citation Trends
Publications
0 total
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies OA
Cited by 11
Semantic Scholar
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials OA
Cited by 561
Semantic Scholar
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Cited by 59
Semantic Scholar
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk OA
Cited by 20
Semantic Scholar
Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab OA
Cited by 332
Semantic Scholar
Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients OA
Cited by 550
Semantic Scholar
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial OA
Cited by 97
Semantic Scholar
CSL112 Enhances Biomarkers of Reverse Cholesterol Transport After Single and Multiple Infusions in Healthy Subjects OA
Cited by 102
Semantic Scholar
Research Topics
Lipoproteins and Cardiovascular Health
(44)
Diabetes, Cardiovascular Risks, and Lipoproteins
(22)
Cancer, Lipids, and Metabolism
(12)
Obesity, Physical Activity, Diet
(10)
Birth, Development, and Health
(9)
Affiliations
Tulane University
Louisiana State University
University of Maryland, Baltimore
Merck & Co., Inc., Rahway, NJ, USA (United States)
Medpace (United States)